SCHEMBL4132292

SCHEMBL4132292

CCCCCCCCCCCC(=O)Nc1ccc(F)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.73
HDAC1 Q13547 2/20 0.73
HDAC2 Q92769 2/20 0.73
HDAC6 Q9UBN7 2/20 0.73
ICMT O60725 1/20 0.67
ALB P02768 1/20 0.67
PSMB11 A5LHX3 2/20 0.62
PSMA7 O14818 2/20 0.62
PSMB1 P20618 2/20 0.62
PSMA1 P25786 2/20 0.62
PSMA2 P25787 2/20 0.62
PSMA3 P25788 2/20 0.62
PSMA4 P25789 2/20 0.62
PSMB8 P28062 2/20 0.62
PSMB9 P28065 2/20 0.62
PSMA5 P28066 2/20 0.62
PSMB4 P28070 2/20 0.62
PSMB6 P28072 2/20 0.62
PSMB5 P28074 2/20 0.62
PSMB10 P40306 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23271170 1.00 HDAC3 (0.73) HDAC3HDAC1HDAC2HDAC6ICMT
SCHEMBL12215281 1.00 HDAC3 (0.73) HDAC3HDAC1HDAC2HDAC6ICMT
Hydrochloric Acid SCHEMBL23271160 0.98 HDAC3 (0.71) HDAC3HDAC1HDAC2HDAC6ICMT
SCHEMBL27561607 0.98 HDAC3 (0.71) HDAC3HDAC1HDAC2HDAC6ICMT
SCHEMBL18425276 0.93 HDAC3 (0.68) HDAC3HDAC1HDAC2HDAC6ICMT
SCHEMBL9510547 0.91 ENPP2 (0.71) HDAC3HDAC1HDAC2HDAC6PSMB11
SCHEMBL675018 0.91 ENPP2 (0.71) HDAC3HDAC1HDAC2HDAC6PSMB11
SCHEMBL9858666 0.91 ENPP2 (0.71) HDAC3HDAC1HDAC2HDAC6PSMB11
SCHEMBL22299223 0.89 HDAC3 (0.59) HDAC3HDAC1HDAC2HDAC6ICMT
SCHEMBL8075597 0.86 TP53 (0.72) HDAC3HDAC1HDAC2HDAC6ICMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOUCH BIONICS LIMITED (GB) 2009-07-30 US disclosed
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOUCH BIONICS LIMITED (GB) 2009-07-30 US disclosed
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOUCH BIONICS LIMITED (GB) 2009-07-30 US disclosed
WO-2009077844-A2 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA QUONOVA LLC (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192192-A1 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA PGLS, TFPI, Q6ZSR9 HDAC3 453/4885HDAC1 742/4885HDAC2 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.